J Gynecol Oncol.
2018 Jan;29(1):e16. 10.3802/jgo.2018.29.e16.
Survival benefit of patients with early-stage ovarian carcinoma treated with paclitaxel chemotherapeutic regimens
- Affiliations
-
- 1School of Health Care Administration, Taipei Medical University, Taipei, Taiwan. chtang@tmu.edu.tw
- 2Graduate Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan.
- 3Taiwan Cancer Registry, Taipei, Taiwan.
- 4Taiwan Blood Services Foundation, Taipei, Taiwan.
- 5Department of Obstetrics and Gynecology, College of Medicine, National Taiwan University, Taipei, Taiwan. wenfangcheng@yahoo.com
- 6School of Medicine, College of Medicine and Big Data Research Centre, Fu-Jen Catholic University, New Taipei City, Taiwan.
- 7Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.
- 8Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei, Taiwan.
- KMID: 2395243
- DOI: http://doi.org/10.3802/jgo.2018.29.e16
Abstract
OBJECTIVE
Adjuvant chemotherapy was introduced in patients with early-stage ovarian cancer (OC). The benefit of standard chemotherapeutic regimens including taxane has not been established.
METHODS
Patients with early-stage OC from the National Health Insurance Research database of Taiwan who received platinum plus cyclophosphamide (CP) or platinum plus paclitaxel (PT) for 3-6 cycles were recruited, and the disease-free survival (DFS) and overall survival (OS) were determined.
RESULTS
A total of 1,510 early-stage OC patients, including 841 who received CP regimen and 699 who received PT regimen, were included. The 2 groups had a similar estimated probability of 5-year DFS (PT vs. CP, 79.0% vs. 77.6%; p=0.410) and OS (84.6% vs. 84.3%; p=0.691). Patients >50 years of age who received the CP regimen had a lower 5-year DFS than the patients ≤50 years of age who received the CP (p<0.001) or PT regimens (p=0.001). Additionally, patients >50 years of age who received the CP regimen had a worse 5-year OS compared with the other 3 groups (p=0.019) (p=0.179 for patients >50 years of age in the PT group; p=0.002 for patients ≤50 years of age in the CP group; and p=0.061 for patients ≤50 years of age in the PT group). Patients with the CP or PT regimen for 3-5 cycles had a similar 5-year DFS and OS compared to 6 cycles (p>0.050).
CONCLUSION
Chemotherapeutic regimens with taxane could be recommended for early-stage OC patients >50 years of age.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Differences of EDR Chemoresistance Assay and Prognosis between Recurrent Micropapillary Serous Ovarian Carcinoma and Serous Ovarian Carcinoma
- Long-term recurrence-free survival of a patient with advanced pure primary ovarian squamous cell carcinoma treated with dose-dense paclitaxel combined with carboplatin
- The correlation of clusterin binding affinity to chemotherapeutic agents with chemoresistance in ovarian cancer cells
- Ovarian Squamous Cell Carcinoma Associated with Endometriosis: Poor Response to Chemotherapy
- Effects of Osteopontin on Normal and Malignant Ovarian Epithelial Cell
